The ACOD1 Knockout KYSE-30 Polyclonal Cells offer a CRISPR/Cas9-mediated gene disruption in ACOD1, produced as a polyclonal knockout cell population from the KYSE-30 human esophageal squamous cell carcinoma line. This product provides a genetically diverse pool of edited cells, each harboring unique loss-of-function mutations, enabling robust bulk analyses while avoiding clonal bias. It is particularly suited for assays where population-level knockout effects are studied, such as pooled screens and biochemical profiling.
KYSE-30 is a widely used esophageal squamous cell carcinoma cell line derived from a well-differentiated tumor. These epithelial cells display hallmark features of squamous carcinomas, including cytokeratin expression, invasive growth, and response to inflammatory mediators. The line is commonly employed to study esophageal cancer pathogenesis, therapeutic resistance, and the interplay between cancer cells and immune components.
The ACOD1 gene encodes aconitate decarboxylase 1, an enzyme that converts the TCA cycle intermediate cis-aconitate to itaconate under pro-inflammatory conditions. Expression is driven by LPS, IFN-??, and TNF-?? through NF-??B and STAT1 transcription factors. Itaconate serves as a key immunometabolite: it inhibits succinate dehydrogenase (SDH), causing succinate accumulation and modulated ROS production; it alkylates KEAP1, releasing NRF2 to induce antioxidant genes; and it directly suppresses NLRP3 inflammasome activation. Therefore, ACOD1 integrates mitochondrial metabolism with cellular defense mechanisms against oxidative stress and inflammation.
In the KYSE-30 context, disrupting ACOD1 enables detailed investigation of itaconate’s role in esophageal cancer cell biology. Esophageal squamous cell carcinomas are often driven by chronic inflammation and oxidative damage, where ACOD1-dependent NRF2 activation could confer a survival advantage. Loss of ACOD1 may render cells more susceptible to inflammatory stress or alter immunogenic signaling through NLRP3 and NF-??B pathways. Additionally, altered SDH activity and succinate levels could impact pseudohypoxic gene expression, potentially affecting metastatic behavior and metabolic reprogramming.
These polyclonal knockout cells are designed for multiple experimental approaches: measuring itaconate by LC-MS, assessing SDH enzyme activity, quantifying ROS, and profiling cytokine secretion via ELISA or multiplex immunoassays. They are ideal for functional studies in cancer metabolism, immunometabolism, and tumor microenvironment research. Validation can be performed by western blotting, RT-qPCR, or DNA sequencing. For further inquiries, contact Ascent Research.
